
If things work out, the Danish company Genmab could earn just about a billion Danish kroner from the recently signed deal with the US company Janssen Biotech.
The deal concerns Genmab’s DuoBody-technology platform, which the company will use to create panels of bispecific antibodies against various disease target combinations identified by Janssen, who will fully finance Genmab’s development work.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app